Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
Insulet to Present at the Jefferies Global Healthcare Conference
Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
May 9 (Reuters) - Insulet Corp (PODD.O), opens new tab reported first-quarter profit that missed market expectations on Thursday, weighed by higher marketing expenses, sending shares of the medical device maker down 3.7% in extended trading.
Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
Nov 2 (Reuters) - Insulet Corp (PODD.O) on Thursday raised its full-year revenue growth forecast after posting strong third-quarter sales, banking on strong demand for its tubeless insulin pumps.
Sept 7 (Reuters) - Insulet Corp's (PODD.O) shares hit an over three-year low on Thursday on concerns that strong demand for a new class of diabetes drugs that also aid in weight loss could hit sales of its insulin pumps.
Aug 8 (Reuters) - Insulet Corp (PODD.O) on Tuesday raised its annual revenue growth forecast and beat second-quarter profit and revenue estimates, on strong demand for its tubeless insulin pumps that are more convenient to use compared to traditional devices.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2023 on August 8, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
In its second such deal in as many days, Insulet has put down another $25 million to acquire technology used in automating insulin delivery.